Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-25-014654
Filing Date
2025-04-21
Accepted
2025-04-21 09:20:30
Documents
20
Period of Report
2025-06-03

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20047013x2_def14a.htm   iXBRL DEF 14A 945467
6 GRAPHIC logo_adc2.jpg GRAPHIC 47456
7 GRAPHIC ny20047013x2_pc01.jpg GRAPHIC 489579
8 GRAPHIC ny20047013x2_pc02.jpg GRAPHIC 1633299
  Complete submission text file 0001140361-25-014654.txt   7250526

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA adct-20250603.xsd EX-101.SCH 3087
3 INLINE XBRL TAXONOMY EXTENSION - DEFINITION LINKBASE adct-20250603_def.xml EX-101.DEF 2506
4 INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE adct-20250603_lab.xml EX-101.LAB 1976
5 INLINE XBRL TAXONOMY EXTENSION - PRESENTATION LINKBASE adct-20250603_pre.xml EX-101.PRE 1657
23 EXTRACTED XBRL INSTANCE DOCUMENT ny20047013x2_def14a_htm.xml XML 105953
Mailing Address BIOPOLE ROUTE DE LA CORNICHE 3B EPALINGES V8 1066
Business Address BIOPOLE ROUTE DE LA CORNICHE 3B EPALINGES V8 1066 41 21 653 02 00
ADC Therapeutics SA (Filer) CIK: 0001771910 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39071 | Film No.: 25851436
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)